` PTGX (Protagonist Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

PTGX
vs
S&P 500

Over the past 12 months, PTGX has significantly outperformed S&P 500, delivering a return of 67% compared to the S&P 500's 9% growth.

Stocks Performance
PTGX vs S&P 500

Loading
PTGX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
PTGX vs S&P 500

Loading
PTGX
S&P 500
Difference
www.alphaspread.com

Performance By Year
PTGX vs S&P 500

Loading
PTGX
S&P 500
Add Stock

Competitors Performance
Protagonist Therapeutics Inc vs Peers

S&P 500
PTGX
ABBV
AMGN
GILD
VRTX
Add Stock

Protagonist Therapeutics Inc
Glance View

Market Cap
3.3B USD
Industry
Biotechnology

Protagonist Therapeutics Inc. stands as a pioneering player in the biopharmaceutical landscape, diligently orchestrating the journey from scientific discovery to therapeutic breakthroughs. Established with the vision to exploit the therapeutic potential of peptides, the company has carved a niche for itself by focusing on innovative peptide-based drug discovery and development. Their proprietary technology platform is designed to genetically engineer and optimize peptides aimed at treating a spectrum of diseases, notably in areas of unmet medical needs such as autoimmune conditions and rare genetic disorders. The fusion of cutting-edge biotechnology and seasoned expertise enables Protagonist to transform promising scientific concepts into viable medicines, paving the way for advancements in patient treatment options. Fueling its growth and revenue potential, Protagonist Therapeutics operates primarily through partnerships and collaborative alliances, as well as progressing its proprietary pipeline. By leveraging strategic collaborations with established pharmaceutical giants, the company garners funding, technological insights, and broader developmental capabilities. This collaborative synergy not only bolsters their research endeavors but also hastens the clinical development and eventual commercialization of their pipeline products. Their ability to secure partnerships and effectively progress their drug candidates through various clinical stages is critical to their financial model, converting scientific innovation into shareholder value and societal impact. The company continues to navigate the complexities of drug development with a steadfast focus on unlocking the therapeutic potential of peptides, aspiring to merge innovation with tangible health benefits.

PTGX Intrinsic Value
15.74 USD
Overvaluation 71%
Intrinsic Value
Price
Back to Top